What is KYTHERA Biopharmaceuticals Receivables Turnover?
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. KYTHERA Biopharmaceuticals's Revenue for the
three
months ended in Jun. 2015 was €0.26 Mil. KYTHERA Biopharmaceuticals's average Accounts Receivable for the
three
months ended in Jun. 2015 was €0.00 Mil.
KYTHERA Biopharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of KYTHERA Biopharmaceuticals's Receivables Turnover
For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KYTHERA Biopharmaceuticals's Receivables Turnover Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where KYTHERA Biopharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
KYTHERA Biopharmaceuticals Receivables Turnover Related Terms
Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
KYTHERA Biopharmaceuticals (FRA:KYT) Business Description
KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:KYT has been successfully added to your 